Zymeworks

Zymeworks Inc. is a clinical-stage biotechnology company based in Vancouver, Canada, founded in 2003. The company specializes in the discovery, development, and commercialization of multifunctional biotherapeutics aimed at treating challenging diseases, including cancer, inflammation, and autoimmune disorders. Zymeworks utilizes advanced protein engineering and proprietary molecular modeling software to create innovative antibody-based therapeutics. Its key technology platforms include the Azymetric™ platform, which allows for the development of bispecific and multispecific antibodies, and the EFECT™ platform, which enhances antibody-dependent cell-mediated cytotoxicity. The company's flagship product, Zanidatamab (Ziihera®), is a bispecific antibody targeting HER2-expressing cancers and is the first of its kind approved in multiple regions for specific cancer treatments. Zymeworks collaborates with global biopharmaceutical companies, licensing its technologies and therapeutics to enhance drug development. The company is dedicated to addressing significant unmet medical needs in oncology and other disease areas through its innovative approaches and strategic partnerships.